TXONE-NETWORKS
25.4.2024 09:05:30 CEST | Business Wire | Press release
TXOne Networks, a leading company in the field of cyber-physical systems (CPS) security, will be presenting its new CPS security platform during the Hannover Messe from 22nd to 26th April 2024 at stand B06 in hall 16: SageOne, which means Wise Man Number One. This central management console provides an overview of the CPS attack surface of the OT environment.
All three TXOne product lines can be centrally controlled, namely Stellar for endpoint protection, Element for security inspection and Edge for network defense. The platform offers integrated OT security across the entire lifecycle of the objects to be protected and enables reliable detection and response to threats.
SageOne essentially covers three main pillars:
- CPS Attack Surface Management: Visibility is a cornerstone for cybersecurity. A clear view of the overall security posture helps identify security focal points in an OT environment. SageOne focuses on operational security by honing in on assets and illuminating the security information of various controls.
- Integrated Lifecycle Protection: Centralized management simplifies cybersecurity governance and achieves collaborative defense. As an abstraction layer, SageOne streamlines the contextualization and consolidation of data across various products. It offers a tailored, task-oriented console designed specifically for executives, security personnel, and plant leaders.
- CPS Threat Detection & Response: Properly handling known threats is absolutely crucial. Coping with unknown threats is equally important. SageOne compiles all security insights from multiple solutions and scouts for potential risks in order to enable early caution and response when needed.
To achieve this goal, the platform includes the following key components:
- Threat intelligence means collecting, analysing and applying knowledge about potential and existing threats against a CPS. The TXOne Threat Research department carries out a large number of investigations into vulnerabilities in Industrial Control Systems (ICS) devices and protocols. It analyses malware and ransomware in connection with Operational Technology (OT) threats. This information can also come from a variety of other sources: Publicly available data, industry reports and private sector information.
- Behaviour-based AI analytics engines use artificial intelligence to monitor and analyse the behaviour of users, devices and systems within a CPS. This advanced analytics engine learns the normal behavioural patterns of these entities and can detect unusual activity or anomalies that could indicate a security threat.
- The Compliance Framework provides a structured approach to compliance with relevant safety standards and regulations. It includes policies, procedures and controls to ensure that every system complies with legal requirements, industry standards and security best practices.
- The Data Visualiser is a tool that transforms complex safety data and metrics into an easy-to-understand visual form. Using diagrams, graphs and network maps, security professionals can recognise patterns and trends as well as anomalies more quickly.
- The Ecosystem Integrator helps to seamlessly integrate different tools and technologies. This includes standardising data formats, promoting the interoperability of different systems and creating a coherent security architecture that covers the entire ecosystem. This enables security forces to obtain a standardised overview of the security situation, automate processes and respond more effectively to threats.
SageOne focuses on the analysis of unexpected behaviour and unknown threats. Suspicious events can be identified by comparing endpoint and network telemetry within the OT-native XDR (Extended Detection and Response) engine. The platform thus combines advanced technologies with a user-friendly interface to ensure the protection of critical infrastructures. To achieve reliable CPS attack surface management, SageOne also offers Asset Centric Visibility to provide full visibility of any device on the network. In addition, the analysis of the attack surface is prioritised and recommendations are made.
To enable a rapid response to threats, SageOne can issue early warnings of suspicious behaviour in the network as part of CPS Threat Detection & Response Orchestration using cross-telemetry analysis.
In addition, Integrated Lifecycle Protection protects devices and systems over their entire service life. The centralised management of the security solutions and the unified defence under one roof contribute to this, resulting in high cost efficiency. With SageOne, TXOne Networks emphasises its commitment to the security and reliability of CPS and continuously drives the development of OT security.
Visit TXOne Networks at the Hannover Messe from 22nd to 26th April 2024 at booth B06 in hall 16.
Follow TXOne Networks on the blog, Twitter and LinkedIn.
About TXOne Networks
TXOne Networks provides OT security products that ensure the reliability and security of industrial control systems and operational technology environments through the OT Zero Trust methodology. TXOne Networks works with both leading industrial manufacturers and critical infrastructure operators to develop practical and business-friendly approaches to OT defence. TXOne Networks offers both network and endpoint-based products to secure OT networks and mission-critical devices in real-time and with high security depth. www.txone.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240420367607/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
